Morning Recap: Biogen Inc. (NASDAQ: BIIB) – The Daily Leicester

This post was originally published on this site

Biogen Inc. (NASDAQ: BIIB) is a large market cap stock with a market cap of 54.5B. It is in the Biotechnology industry and sector Healthcare, with a current P/E of 16.16, a forward P/E of 11.41 and EPS of 15.95. At a stock price of 257.64 (-0.34%) it has a dividend yield of (Data Not Available).

EPS growth for the last five years have been 27.40%, more recently this last year it has grown by 10.30%. The next year growth is going to be about 10.23% and more long-term 6.34% after five years. EPS growth quarter over quarter is -21.80%. Sales growth for the past five years have been 17.80% and sales growth quarter over quarter is 3.10%.

For performance, Biogen Inc. the past week has seen a gain of -1.39%. For the last month performance for Biogen Inc. is -5.99%. While the last quarter is -9.64% and half year, -19.28%. Finally for the year, performance is -3.24%.

The 52-week high for Biogen Inc., is at -22.78%, and for the 52-week low it comes to a value of 15.52%. The 20-day simple moving average is -4.07% and -11.51% for the 200-day simple moving average.

Volatility for the week is at 1.87%, and for the month it is 1.73%. Biogen Inc., has a target price of 313.94.

In terms of debt, long term debt/equity is 0.52, and for total debt/equity Biogen Inc. has 0.57. The gross margin is 86.60%, while operating margin is 41.60%, the profit margin is 30.20%. The current ratio is 2.3 and the quick ratio is 2.

Insider ownership is at 0.10%, with instituitional ownership at 91.70%. Biogen Inc. has a payout ratio of 0.00%. With the total shares outstanding coming to 211.54. The shares float is 211.48, with the float short at 1.19%, with short ratio coming to 1.61.

In terms of returns, the return on assets see Biogen Inc., get 15.90%, with its returns on investment at 21.00%. Return on equity is 29.50%. So will the investors see the target price of 313.94, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

 Biogen Inc. (NASDAQ: BIIB)

This post was originally published on *this site*